Modular manufacturing: The key to unlocking mRNA expansion?
The evolving mRNA landscape has been marked by rapid advancements and a broadening scope of applications, primarily driven by the …
The evolving mRNA landscape has been marked by rapid advancements and a broadening scope of applications, primarily driven by the …
Against the backdrop of geopolitical tensions and economic measures such as tariffs, which are influencing supply chains across numerous industries, …
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II …
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by …
Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index …
According to GlobalData analysis, currently marketed and pipeline cell therapy assets in oncology will generate sales of around $25bn by …
Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index …
Contract development and manufacturing organisations (CDMOs) worldwide are facing a multitude of challenges, which are heightened considerably in oncology by …
Handing over your molecule is a big step for emerging biotechs. The process of developing new drugs is complex and …
LEO Pharma has reported positive outcomes from the 16-week interim analysis of the randomised Phase IIIb ADHAND trial of fully …
The US Food and Drug Administration (FDA) has approved Purespring Therapeutics’ investigational new drug (IND) application for PS-002, allowing the …
Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around …
US President Donald Trump's 200% tariff threat on the pharmaceutical industry is a "shock" that will reverberate through global supply …
Upstream Bio has dosed the first subject in the randomised Phase II trial of verekitug, an antibody antagonist targeting the …
Beacon Therapeutics has completed the enrolment in its randomised, registrational Phase II/III VISTA trial of laru-zova (laruparetigene zovaparvovec) as a …